A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

• Status: Recruiting
• Trial end date: 2030-08-28

Summary

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Daiichi Sankyo
• Treatments: Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Durvalumab; Epirubicin; Olaparib; Paclitaxel; Pembrolizumab